CANF
Can-fite Biopharma·AMEX
--
--(--)
--
--(--)
CANF fundamentals
Can-fite Biopharma (CANF) released its earnings on Aug 15, 2024: revenue was -- (YoY --), beat estimates; EPS was -- (YoY --), met estimates.
Revenue / YoY
--
--
EPS / YoY
--
--
Report date
Aug 15, 2024
EPS
Actual | -9.009 | -3.0027 | -1.6014 | -2.4022 | 0 | -1.2011 | -1.9017 | -3.0027 | 0 | -0.8007 | -0.93 | -1.11 | 0 | -0.35 | -0.265 | -0.395 | |||||||||
Forecast | -4.1537 | -2.5024 | -2.3521 | -1.3512 | -1.3512 | -1.5515 | -0.7006 | -1.7015 | -1.4013 | -0.734 | -0.9008 | -0.9139 | -0.71 | -0.6167 | -0.43 | -0.265 | |||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -116.89% | -19.99% | +31.92% | -77.78% | +100.00% | +22.58% | -171.44% | -76.47% | +100.00% | -9.09% | -3.24% | -21.46% | +100.00% | +43.25% | +38.37% | -49.06% | 0.00% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | 198.00K | 302.00K | 205.50K | 175.00K | 148.00K | 250.00K | 251.50K | 204.00K | 205.00K | 409.00K | 204.00K | 200.00K | 196.00K | 198.00K | 198.00K | 177.50K | -- |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | 500.00K | 250.00K | 500.00K | 500.00K | 300.00K | 218.33K | 140.00K | 266.67K | 133.33K | 250.00K | 300.00K | 500.00K | -- | 200.00K | 200.00K | 200.00K | -- |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -60.40% | +20.80% | -58.90% | -65.00% | -50.67% | +14.50% | +79.64% | -23.50% | +53.75% | +63.60% | -32.00% | -60.00% | 0.00% | -1.00% | -1.00% | -11.25% | 0.00% |
Earnings Call
You can ask Aime
What is the market's earnings forecast for Can-fite Biopharma next quarter?What were the key takeaways from Can-fite Biopharma's earnings call?What is the revenue and EPS growth rate for Can-fite Biopharma year over year?What factors drove the changes in Can-fite Biopharma's revenue and profit?What guidance did Can-fite Biopharma's management provide for the next earnings period?What is Can-fite Biopharma's latest dividend and current dividend yield?What does Can-fite Biopharma do and what are its main business segments?What were the key takeaways from Can-fite Biopharma’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
